Metrics as of 10/16/2026, 08:32 AM (Berlin time), refresh in progress.
Kura Oncology Stock
Kura Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Troy Wilson
- Employees
- 260
- Market cap
- $863 M
- IPO
- 16/09/2015
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes…
Kura Oncology stock: price history
1D
+0.9%
1W
-7.8%
1M
-14.2%
6M
+8.5%
YTD
-6.6%
1Y
-5.7%
2Y
-46.7%
5Y
-46.2%
10Y
+74.2%
Next earnings date
Next earnings date
03/11/2026 (in 17 days)
Volatility around earnings
~12% weaker price swings than usual
Kura Oncology stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
1 more assignment (Enabler/Second row) Pro-only.
Kura Oncology is a clinical-stage biopharmaceutical company focused on developing cancer therapeutics. A central research area is the development of Menin inhibitors such as Ziftomenib for the treatment of solid tumors, as well as research approaches for metabolic diseases such as diabetes. The current revenue structure is generated almost exclusively through collaboration agreements, which account for over 96 percent of revenues, while a marginal share comes from product sales.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about Kura Oncology
Analyst assessment of Kura Oncology
PRICE TARGET LOW
US$24.00
CONSENSUS
US$24.00
MEDIAN
US$24.00
PRICE TARGET HIGH
US$24.00
0
STRONG BUY
15
BUY
2
HOLD
0
SELL
0
STRONG SELL
17
TOTAL · Buy
As of: 24/08/2026
Kura Oncology stock metrics
P/E
-2.88
P/B
17.8
EV/EBITDA
-2.78
RETURN ON EQUITY
-141.1%
NET MARGIN
-327.3%
DEBT/EQUITY
0.5
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
97.2%
FLOAT SHARES
86,489,097
AVG. DAILY VOLUME (30D)
1,774,683
Insider transactions (SEC)
Bair Teresa Brophy
Powl Brian T.
FORD KATHLEEN
FORD KATHLEEN
Leoni Mollie
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.9%
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Kura Oncology stock
What does Kura Oncology do?
Kura Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Troy Wilson, the company employs around 260 people.
The IPO was on 16/09/2015; the stock trades on NASDAQ under the ticker KURA.
What do analysts say about Kura Oncology stock?
17 analysts rate the stock, the consensus is Buy (as of 24/08/2026).
The average price target is US$24.00, ranging from US$24.00 to US$24.00, with a median of US$24.00.
This is an external assessment, not a statement by Market Jury.
When does Kura Oncology report next?
The next earnings date is 03/11/2026.
Around past earnings, price swings were roughly -12% stronger than usual.
Does Kura Oncology pay a dividend?
No, Kura Oncology currently does not pay a dividend.
Which stocks are comparable to Kura Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Kura Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Kura Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.